Comparison of Botox^® or Prosigne^® and Facial Nerve Blockade as Adjuvant in Chronic Migraine

Gabriela R. Lauretti, Christiane P. Rosa, Antônio Kitayama, Bruno C. P. Lopes

School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
Sirio Libanes Hospital, São Paulo, Brazil.

DOI: 10.4236/jbise.2014.78047                

Abstract

Background: The treatments suggested for chronic migraine (CM) include: 1) intramuscular (im) botulinum toxin (BTX) every 12 weeks, and 2) blockade of peripheral nerves of the head. The present study evaluated the efficacy of facial nerve blockade in combination with a single administration of different low BTX. Methods: Forty patients with CM submitted to unilateral facial nerve blockade (supraorbital, supratrochlear and auriculotemporal) were divided into 4 randomized groups in a double-blind manner in order to receiveim, after 7 days: 25 IU Botox^® (Botox group), 25 IU Prosigne^® (25-Pro group), 33.3 IU Prosigne^® (33-Pro group) or saline (control group), with the dose divided for application to 10 sites in the frontal and bilateral temporal regions. Analgesia and adverse effects were evaluated: 1) before blockade of the facial nerves and 2) 4 weeks, 3) 8 weeks and 4) 12 weeks after BTX-A or saline application (HC clinical trial no. 12465). Results: Botox^® (25 IU) or Prosigne^® (33.3 IU) resulted in at least seven-day intervals between headache attacks associated with 70% reduction in frequency and intensity of crises over 12 weeks (P < 0.05), while the 25 IU dose of Prosigne^® resulted in 8 weeks of analgesia. The conversion factor between Botox^® and Prosigne^® was 1:1.3. Conclusions: Im application of Botox^® (25 IU) or Prosigne^® (33.3 IU) one week after nerve blockade on the painful side was equally effective for 12 weeks in patients with chronic daily headache, with the conversion factor between Botox^® and Prosigne^® being 1:1.3.

Keywords

Botox, Prosigne, Chinese Toxin Botulin, Chronic Migraine, Peripheral Blocks

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Frampton, J.E. (2012) OnabotulinumtoxinA (BOTOX®): A Review of Its Use in the Prophylaxis of Headaches in Adults with Chronic Migraine. Drugs, 72, 825-845. http://dx.doi.org/10.2165/11208880-000000000-00000
[2]	SeyedSaadat, S.M., Hosseininezhad, M., Bakhshayesh, B., Hoseini, M. and Naghipour, M. (2013) Epidemiology and Clinical Characteristics of Chronic Daily Headache in a Clinic-Based Cohort of Iranian Population. Neurological Sciences [Epub Ahead of Print]
[3]	Ashkenazi, A. and Blumenfeld, A. (2013) Onabotulinumtoxin-A for the Treatment of Headache. Headache, 53, 54-61. http://dx.doi.org/10.1111/head.12185
[4]	Silberstein, S.D., Blumenfeld, A.M., Cady, R.K., Turner, I.M., Lipton, R.B., Diener, H.C., Aurora, S.K., Sirimanne, M., DeGryse, R.E., Turkel, C.C. and Dodick, D.W. (2013) Onabotulinumtoxin-A for Treatment of Chronic Migraine: PREEMPT 24-Week Pooled Subgroup Analysis of Patients Who Had Acute Headache Medication Overuse at Baseline. Journal of the Neurological Sciences, 331, 48-56. http://dx.doi.org/10.1016/j.jns.2013.05.003
[5]	Aurora, S.K., Dodick, D.W., Diener, H.C., Degryse, R.E., Turkel, C.C., Lipton, R.B. and Silberstein, S.D. (2014) Onabotulinumtoxin-A for Chronic Migraine: Efficacy, Safety, and Tolerability in Patients Who Received All Five Treatment Cycles in the PREEMPT Clinical Program. Acta Neurologica Scandinavica, 129, 61-70. http://dx.doi.org/10.1111/ane.12171
[6]	Levin, M. (2010) Nerve Blocks in the Treatment of Headache. Neurotherapeutics, 7, 197-203. http://dx.doi.org/10.1016/j.nurt.2010.03.001
[7]	Ilhan Alp, S. and Alp, R. (2013) Supraorbital and Infraorbital Nerve Blockade in Migraine Patients: Results of 6-Month Clinical Follow-Up. European Review for Medical and Pharmacological Sciences, 17, 1778-1781.
[8]	Schuster, L. (2003) Highlights of the 11th Congress of the International Headache Society, Held September 13-16, 2003, in Rome, Italy. Updating the Headache Classification System. Drug News & Perspectives, 16, 692-697.
[9]	Wan, X. and Tang, X. (1998) Comparison of Botox and a Chinese Type A Botulinum Toxin in Cervical Dystonia. Zhong Hua Yi Xue Za Zhi, 78, 131-134.
[10]	Tang, X. and Wan, X. (2000) Comparison of Botox with a Chinese Type A Botulinum Toxin. Chinese Medical Journal (England), 113, 794-798.
[11]	Guarany, F.C., Picon, P.D., Guarany, N.R., dos Santos, A.C., Chiella, B.P., Barone, C.R., Fendt, L.C. and Schestatsky, P. (2013) A Double-Blind, Randomised, Crossover Trial of Two Botulinum Toxin Type a in Patients with Spasticity. PLoS One, 8, Article ID: e56479. http://dx.doi.org/10.1371/journal.pone.0056479
[12]	Quagliato, E.M., Carelli, E.F. and Viana, M.A. (2010) A Prospective, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Type a Botulinum Toxins Botox and Prosigne in the Treatment of Cervical Dystonia. Clinical Neuropharmacology, 33, 22-6.
[13]	Silberstein, S.D., Stark, S.R., Lucas, S.M., Christie, S.N., Degryse, R.E. and Turkel, C.C. (2005) BoNTA-039 Study Group. Botulinum Toxin Type A for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double-Blind, Placebo-Controlled Trial. Mayo Clinic Proceedings, 80, 1126-1137. http://dx.doi.org/10.4065/80.9.1126
[14]	Keller, J.E., Cai, F. and Neale, E.A. (2004) Uptake of Botulin Neurotoxin into Cultured Neurons. Biochemistry, 43, 526-532. http://dx.doi.org/10.1021/bi0356698
[15]	Gracies, J.M. (2004) Physiological Effects of Botulinum Toxin in Spasticity. Movement Disorders, 19, 120-128. http://dx.doi.org/10.1002/mds.20065
[16]	Argoff, C.E. (2002) A Focused Review on the Use of Botulinum Toxins for Neuropathic Pain. Clinical Journal of Pain, 18, 177-181. http://dx.doi.org/10.1097/00002508-200211001-00010
[17]	Klein, A.W. (2004) The Therapeutic Potential of Botulinum Toxin. Dermatologic Surgery, 30, 452-455. http://dx.doi.org/10.1111/j.1524-4725.2004.30118.x
[18]	Voller, B., Sycha, T., Gustorff, B., Schmetterer, L., Lehr, S., Eichler, H.G., Auff, E. and Schnider, P. (2003) A Randomized, Double-Blind, Placebo Controlled Study on Analgesic Effects of Botulinum Toxin A. Neurology, 61, 940-944. http://dx.doi.org/10.1212/01.WNL.0000086374.92906.6A
[19]	Sycha, T., Samal, D., Chizh, B., Lehr, S., Gustorff, B., Schnider, P. and Auff, E. (2006) A Lack of Antinociceptive or Antiinflamatory Effect of Botulinum Toxin A in an Inflammatory Human Pain Model. Anesthesia & Analgesia, 102, 509-516. http://dx.doi.org/10.1213/01.ane.0000194447.46763.73
[20]	Aoki, K.R. (2003) Evidence for Antinociceptive Activity of Botulinum Toxin Type A in Pain Management. Headache, 43, 9-15. http://dx.doi.org/10.1046/j.1526-4610.43.7s.3.x
[21]	Afridi, S.K., Shields, K.G., Bhola, R. and Goadsby, P.J. (2006) Greater Occipital Nerve Injection in Primary Headache Syndromes—Prolonged Effects from a Single Injection. Pain, 122, 126-129. http://dx.doi.org/10.1016/j.pain.2006.01.016
[22]	Sjaastad, O., Petersen, H.C. and Bakketeig, L.S. (2005) Supraorbital Neuralgia. Vaga Study of Headache Epidemiology. Cephalalgia, 25, 296-304. http://dx.doi.org/10.1111/j.1468-2982.2004.00856.x
[23]	Bogduk, N. (2004) Role of Anesthesiologic Blockade in Headache Management. Current Pain and Headache Reports, 8, 399-403. http://dx.doi.org/10.1007/s11916-996-0014-2
[24]	Stillman, M. (2006) Steroid Hormones in Cluster Headaches. Current Pain and Headache Reports, 10, 147-152. http://dx.doi.org/10.1007/s11916-006-0027-x
[25]	Wang, S., Lim, G., Zeng, Q., Sung, B., Yang, L.L. and Mao, J.R. (2005) Central Glucocorticoid Receptors Modulate the Expression and Function of Spinal NMDA Receptors after Peripheral Nerve Injury. Journal of Neuroscience, 25, 488-495. http://dx.doi.org/10.1523/JNEUROSCI.4127-04.2005
[26]	Damen, L., Bruijn, J., Verhagen, A.P., Berger, M.Y., Passchier, J. and Koes, B.W. (2006) Prophylactic Treatment of Migraine in Children. Part 2. A Systematic Review of Pharmacological Trials. Cephalalgia, 26, 497-505. http://dx.doi.org/10.1111/j.1468-2982.2005.01047.x
[27]	Kroin, J.S., Buvanendran, A., Beck, D.R., Topic, J.E., Watts, D.E. and Tuman, K.J. (2004) Clonidine Prolongation of Lidocaine Analgesia after Sciatic Nerve Block in Rats Is Mediated via the Hyperpolarization-Activated Cation Current, Not by α-Adrenoreceptors. Anesthesiology, 101, 488-494. http://dx.doi.org/10.1097/00000542-200408000-00031
[28]	Liu, B.G. and Eisenach, J.C. (2005) Hyperexcitability of Axotomized and Neighboring Unaxotomized Sensory Neurons Is Reduced Days after Perineural Clonidine at the Site of Injury. Journal of Neurophysiology, 94, 3159-3167. http://dx.doi.org/10.1152/jn.00623.2005
[29]	Torelli, P. and Manzoni, G.C. (2004) Cluster Headache: Symptomatic Treatment. Neurological Sciences, 25, 119-122. http://dx.doi.org/10.1007/s10072-004-0267-7